A new analysis by ProPublica finds that many doctors in the U.S. prescribe brand-name drugs to Medicare patients when generics can be dramatically cheaper — and it's costing taxpayers hundreds of millions a year.
Makers of patented drugs sometimes pay generic drug makers not to copy their drugs when they go off patent, allowing them to keep charging high prices. The U.S. Supreme Court says the FTC can challenge such deals.
GlaxoSmithKline, the huge British drug-maker, will pay $3 billion in fines and compensation to the U.S. government and the states. They are in trouble for marketing drugs for off-label uses of its drugs.